Ask AI
ProCE Banner Activity

Debating Optimal Neoadjuvant Therapy and Future Considerations on the Horizon for HR+/HER2- EBC: Downloadable Slides

Slideset Download

Download this slideset to review the latest data on neoadjuvant treatment and future considerations for patients with HR+/HER2- early breast cancer.

Released: May 12, 2021

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Lilly

Faculty Disclosure

Primary Author

Sara M. Tolaney, MD, MPH

Chief, Breast Oncology
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Sara M. Tolaney, MD, MPH: consultant/advisor/speaker: Aadi Bio, Artios Pharma, Arvinas, AstraZeneca, Atkis Oncology, Avenzo Therapeutics, Bayer, BeOne Therapeutics, Bicycle Therapeutics, BioNTech, Blueprint Medicines, Boehringer Ingelheim, Bristol Myers Squibb/Systimmune, Celcuity, Circle Pharma, Cullinan Oncology, Daiichi Sankyo, eFFECTOR, Eisai, Gilead, GNE/Roche, Hengrui USA, Jazz, Johnson & Johnson/Ambrx, Launch Therapeutics, Lilly, Menarini/Stemline, Merck, Mersana, Natera, Novartis, Pfizer/SeaGen, Reveal Genomics, Sumitovant Biopharma, Summit Therapeutics, Tango Therapeutics, Zuellig Pharma; researcher (paid to institution): AstraZeneca, Bristol Myers Squibb, Daiichi Sankyo, Exelixis, Genentech/Roche, Gilead, Jazz, Lilly, Menarini/Stemline, Merck, NanoString Technologies, Novartis, OncoPep, Pfizer/SeaGen; other financial or material support: Arvinas, Gilead, Jazz, Lilly, Pfizer, Roche.